SCHEMBL2432392

SCHEMBL2432392

CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(S(=O)(=O)NC)cc32)c1-c1ccc(F)cc1F

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.68
PRKAA1 Q13131 12/20 0.68
PRKAA2 P54646 11/20 0.68
PDGFRB P09619 7/20 0.68
FGFR1 P11362 5/20 0.68
FLT3 P36888 4/20 0.68
CSF1R P07333 3/20 0.68
EGFR P00533 3/20 0.68
PLK4 O00444 2/20 0.68
DCLK1 O15075 2/20 0.68
PDPK1 O15530 2/20 0.68
DAPK3 O43293 2/20 0.68
ROCK2 O75116 2/20 0.68
RPS6KA5 O75582 2/20 0.68
RPS6KA4 O75676 2/20 0.68
MAP4K4 O95819 2/20 0.68
CHEK2 O96017 2/20 0.68
NTRK1 P04629 2/20 0.68
INSR P06213 2/20 0.68
LCK P06239 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432387 1.00 KDR (0.68) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL4851507 0.88 KDR (0.75) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL2438130 0.86 KDR (0.68) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL2438125 0.86 KDR (0.68) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL15202707 0.86 KDR (0.71) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL4789089 0.83 KDR (0.76) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL4810470 0.82 KDR (0.80) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL4810472 0.82 KDR (0.80) KDRPRKAA1PRKAA2PDGFRBFGFR1
Sunitinib SCHEMBL2726232 0.82 KDR (0.95) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL143543 0.82 KDR (0.77) KDRPRKAA1PRKAA2PDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803829-B2 Use of a kinase inhibitor for the treatment of particular resistant tumors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-09-28 US claimed
US-20100035876-A1 Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-02-11 US claimed
US-20100022532-A1 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 US claimed
EP-2007380-A2 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS Nerviano Medical Sciences S.r.l. (IT) 2008-12-31 EP claimed
EP-2004180-A2 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS Nerviano Medical Sciences S.r.l. (IT) 2008-12-24 EP claimed
WO-2007113198-A2 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-10-11 WO claimed
WO-2007113212-A2 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-10-11 WO claimed
US-8084455-B2 Use of a kinase inhibitor for the treatment of particular resistant tumors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-12-27 US disclosed
EP-2007380-B1 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS NERVIANO MEDICAL SCIENCES SRL (IT) 2011-09-14 EP disclosed
US-7803829-B2 Use of a kinase inhibitor for the treatment of particular resistant tumors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-09-28 US disclosed
US-20100035876-A1 Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-02-11 US disclosed
US-20100022532-A1 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 US disclosed
WO-2008145398-A1 4-ARYLPYRROLE SUBSTITUTED 2-INDOLINE DERIVATIVES ACTIVE AS PROTEIN KINASE INHIBITORS PFIZER ITALIA S.R.L. (IT) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022532-A1 USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS ABL1, ABL2, LTK KDR 739/4885PRKAA1 82/4885PRKAA2 155/4885
US-20100035876-A1 Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors ABL1, LTK, ABL2 KDR 732/4885PRKAA1 84/4885PRKAA2 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.